<?xml version="1.0" encoding="UTF-8"?>
<p id="p0050">The case of chikungunya virus (CHIKV) is of specific interest: chloroquine showed promising antiviral activity 
 <italic>in vitro</italic> (
 <xref rid="bib5" ref-type="bibr">Coombs et al., 1981</xref>; 
 <xref rid="bib7" ref-type="bibr">Delogu and de Lamballerie, 2011</xref>), but was shown to enhance alphavirus replication in various animal models (
 <xref rid="bib18" ref-type="bibr">Maheshwari et al., 1991</xref>; 
 <xref rid="bib23" ref-type="bibr">Roques et al., 2018</xref>; 
 <xref rid="bib25" ref-type="bibr">Seth et al., 1999</xref>), most probably because of the immune modulation and anti-inflammatory properties of chloroquine 
 <italic>in vivo</italic> (
 <xref rid="bib4" ref-type="bibr">Connolly et al., 1988</xref>; 
 <xref rid="bib14" ref-type="bibr">Katz and Russell, 2011</xref>; 
 <xref rid="bib24" ref-type="bibr">Savarino et al., 2003</xref>). In a nonhuman primate model of CHIKV infection, chloroquine treatment was shown to exacerbate acute fever and delay the cellular immune response, leading to an incomplete viral clearance (
 <xref rid="bib23" ref-type="bibr">Roques et al., 2018</xref>). A clinical trial conducted during the chikungunya outbreak in 2006 in RÃ©union Island showed that oral chloroquine treatment did not improve the course of the acute disease (
 <xref rid="bib6" ref-type="bibr">De Lamballerie et al., 2008</xref>) and that chronic arthralgia on day 300 post-illness was more frequent in treated patients than in the control group (
 <xref rid="bib23" ref-type="bibr">Roques et al., 2018</xref>). Altogether, the assessment of previous trials indicates that, to date, no acute virus infection has been successfully treated by chloroquine in humans.
</p>
